Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
July 2014

Do Children Taking SGAs Get Metabolic Monitoring?
Careful monitoring of adverse effects of psychotropic drugs in general and second-generation antipsychotics in particular falls below recommended standards for children and adolescents.

A New Treatment for Parkinson Disease Psychosis
In a placebo-controlled study of patients with Parkinson disease and psychosis, the 5-HT-2A receptor inverse agonist pimavanserin improved psychotic symptoms and did not worsen motor signs.

Ramelteon (Rozerem) to Prevent Delirium?
Preliminary results from using the melatonin-receptor agonist ramelteon (Rozerem) in hospitalized patients to prevent delirium are encouraging.

In Brief
Starting Dose of Eszopiclone Lowered to Avoid Next-Day Impairment; Study Examines Determinants of Antipsychotic Treatment Response

Anxiolytics, Hypnotics, and Mortality Risk
In a retrospective cohort study, a significant association was found between the use of anxiolytic and hypnotic drugs and an increased risk of death.

Download a Sample Issue of BTP

A following sample issue of Biological Therapies in Psychiatry is available in .pdf format. These files require Adobe Acrobat© Reader to view. (If you do not currently have the Acrobat Reader, click here to download).

Download a free sample pdf of BTP



One, two and three-year subscriptions are immediately available. Each subscription allows you full online access to current and recent issues, a searchable online database, downloadable audio files, and a printed newsletter that will be mailed to you monthly. You'll receive timely, accurate information at a very reasonable price. A one-year US subscription is only $86.00.


Subscribe